Contemporary approaches in the management of uterine leiomyomas.

[1]  H. Zhang,et al.  Curcumol, a major terpenoid from Curcumae Rhizoma, attenuates human uterine leiomyoma cell development via the p38MAPK/NF-κB pathway. , 2023, Journal of ethnopharmacology.

[2]  Y. Na,et al.  Effects of long-term intermittent pharmacological therapy with ulipristal acetate on reducing the volume of uterine fibroids and relieving symptoms. , 2023, Minerva obstetrics and gynecology.

[3]  A. Al-Hendy,et al.  Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. , 2022, American journal of obstetrics and gynecology.

[4]  A. Al-Hendy,et al.  Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas , 2022, Obstetrics and gynecology.

[5]  Mee-Ran Kim,et al.  The Potential of Transforming Growth Factor-beta Inhibitor and Vascular Endothelial Growth Factor Inhibitor as Therapeutic Agents for Uterine Leiomyoma , 2022, International journal of medical sciences.

[6]  F. Petraglia,et al.  Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials , 2022, The Lancet.

[7]  L. Aaltonen,et al.  Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate , 2022, Human molecular genetics.

[8]  H. Tournaye,et al.  Ultrasonographic appearance of the endometrium after saline infusion in women presenting with PRM-associated endometrial changes, due to the use of ulipristal acetate , 2022, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[9]  W. Bednarek,et al.  Immunohistochemical Expression of Vitamin D Receptor in Uterine Fibroids , 2022, Nutrients.

[10]  S. Chiuve,et al.  Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids , 2022, British journal of clinical pharmacology.

[11]  Malak El Sabeh,et al.  Simvastatin reduces plasma membrane caveolae and caveolin-1 in uterine leiomyomas. , 2022, Life sciences.

[12]  A. Al-Hendy,et al.  Relugolix Combination Therapy for Uterine Leiomyoma–Associated Pain in the LIBERTY Randomized Trials , 2022, Obstetrics and gynecology.

[13]  A. Takeda.  Short‐term administration of oral relugolix before single‐port laparoscopic‐assisted vaginal hysterectomy for symptomatic uterine myomas: A retrospective comparative study with leuprorelin injection , 2022, The journal of obstetrics and gynaecology research.

[14]  Harsha S Gaikwad,et al.  Association between serum vitamin D level and uterine fibroid in premenopausal women in Indian population. , 2022, Drug discoveries & therapeutics.

[15]  Qiwei Yang,et al.  Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF‐β3 and Wnt/β‐Catenin pathways , 2022, Journal of cellular and molecular medicine.

[16]  Hsin-Yuan Chen,et al.  An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women , 2022, Expert opinion on pharmacotherapy.

[17]  W. Catherino,et al.  Relugolix and elagolix directly inhibit leiomyoma extracellular matrix production in 2-dimesnional and 3-dimensional cell cultures. , 2022, F&S science.

[18]  H. Hoshiai,et al.  Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial , 2021, BMC Women's Health.

[19]  F. Facchinetti,et al.  Vitamin D and green tea extracts for the treatment of uterine fibroids in late reproductive life: a pilot, prospective, daily-diary based study. , 2021, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[20]  S. Afrin,et al.  Simvastatin inhibits Wnt/β-catenin pathway in uterine leiomyoma. , 2021, Endocrinology.

[21]  J. Varinot,et al.  Ulipristal Acetate Modifies miRNA Expression in Both Superficial and Basal Layers of the Human Endometrium , 2021, Journal of clinical medicine.

[22]  E. Ng,et al.  Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids. , 2021, Journal of ethnopharmacology.

[23]  Sangam Jha,et al.  Safety and efficacy of two repeated cycles of ulipristal acetate in the management of symptomatic uterine fibroid among Indian women , 2021, Przeglad menopauzalny = Menopause review.

[24]  Qiwei Yang,et al.  Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. , 2021, Pharmacological research.

[25]  Ippei Nakagawa,et al.  A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy , 2021, BMC Women's Health.

[26]  M. Piasecka,et al.  Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids , 2021, Journal of clinical medicine.

[27]  B. Ploeger,et al.  Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation , 2021, British journal of clinical pharmacology.

[28]  S. Garzon,et al.  Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas , 2021, Expert opinion on investigational drugs.

[29]  Y. Osuga,et al.  Ulipristal acetate simultaneously provokes antiproliferative and proinflammatory responses in endometrial cancer cells , 2021, Heliyon.

[30]  Hua Xu,et al.  Treatment of leiomyomatosis peritonealis disseminata with goserelin acetate: A case report and review of the literature , 2021, World journal of clinical cases.

[31]  Md Soriful Islam,et al.  Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids , 2021, Clinical and translational medicine.

[32]  D. Vieira,et al.  Acute liver failure requiring transplantation: A possible link to ulipristal acetate treatment? , 2021, Basic & clinical pharmacology & toxicology.

[33]  P. Vázquez,et al.  Dual agonist–antagonist effect of ulipristal acetate in human endometrium and myometrium , 2021, Expert review of molecular diagnostics.

[34]  Y. Osuga,et al.  Phase III long‐term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids , 2021, The journal of obstetrics and gynaecology research.

[35]  F. Peng,et al.  Ameliorative Effects of Component Chinese Medicine From Curcumae Rhizoma and Sparganii Rhizoma, a Traditional Herb Pair, on Uterine Leiomyoma in a Rat Model , 2021, Frontiers in Public Health.

[36]  C. Castelo-Branco,et al.  Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up , 2021, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[37]  K. Barnhart,et al.  Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis , 2021, F&S reports.

[38]  Karen C. Wang,et al.  A Phase I Clinical Trial to Assess Safety and Tolerability of Injectable Collagenase in Women with Symptomatic Uterine Fibroids , 2021, Reproductive Sciences.

[39]  S. Salama,et al.  Glucose and fatty acid metabolism involved in the protective effect of metformin against ulipristal-induced endometrial changes in rats , 2021, Scientific Reports.

[40]  Alistair R W Williams,et al.  The endometrial response to modulation of ligand-progesterone receptor pathways is reversible. , 2021, Fertility and sterility.

[41]  Breanne E. McCarthy,et al.  A-kinase anchoring protein 13 interacts with the vitamin D receptor to alter vitamin D-dependent gene activation in uterine leiomyoma cells. , 2021, F&S science.

[42]  A. Tinelli,et al.  Nutraceuticals in fibroid management after ulipristal acetate administration: An observational study on patients’ compliance , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[43]  M. Schiavi,et al.  Management of women with uterine fibroids in reproductive center: retrospective analysis of clinical and reproductive outcomes. , 2021, Minerva obstetrics and gynecology.

[44]  Y. Osuga,et al.  Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial. , 2021, Fertility and sterility.

[45]  B. Moradi,et al.  The Effect of Vitamin D Deficiency on Overgrowth of Uterine Fibroids: A Blinded Randomized Clinical Trial , 2021, International journal of fertility & sterility.

[46]  Mohamed Ali,et al.  Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women , 2021, Expert review of clinical pharmacology.

[47]  F. Peng,et al.  Inhibition of Fibroblast Activation in Uterine Leiomyoma by Components of Rhizoma Curcumae and Rhizoma Sparganii , 2021, Frontiers in Public Health.

[48]  A. Al-Hendy,et al.  Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. , 2021, The New England journal of medicine.

[49]  E. Yoon,et al.  Use of ulipristal acetate and risk of liver disease: a nationwide cohort study. , 2021, The Journal of clinical endocrinology and metabolism.

[50]  M. Piasecka,et al.  Markers of Cellular Proliferation, Apoptosis, Estrogen/Progesterone Receptor Expression and Fibrosis in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids , 2021, Journal of clinical medicine.

[51]  E. Saffarieh,et al.  The effect of N‐acetyl cysteine on the volume of uterine leiomyoma: A randomized clinical trial , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[52]  J. Sehouli,et al.  Effects of epigallocatechin gallate-enriched green tea extract capsules in uterine myomas: results of an observational study , 2021, Archives of Gynecology and Obstetrics.

[53]  S. Bhatt,et al.  Effect of Vitamin D3 Supplementation on Symptomatic Uterine Leiomyoma in Women with Hypovitaminosis D , 2021, Journal of mid-life health.

[54]  B. Mozzanega.  Ulipristal Acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya. , 2020, Journal of hepatology.

[55]  A. Agostini,et al.  Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids. , 2020, Reproductive biomedicine online.

[56]  G. Ricci,et al.  Proteins involved in oxidative stress in leiomyoma tissues treated with ulipristal acetate. , 2020, Molecular medicine reports.

[57]  J. Bosmans,et al.  A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: Protocol of the MYOMEX-2 trial. , 2020, European journal of obstetrics, gynecology, and reproductive biology.

[58]  S. Vitale,et al.  Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study , 2020, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

[59]  Z. Falahati,et al.  CYP24A1 expression analysis in uterine leiomyoma regarding MED12 mutation profile , 2020, Archives of Gynecology and Obstetrics.

[60]  Y. Osuga,et al.  Prolapse of a pedunculated uterine leiomyoma through the cervix during GnRH antagonist treatment: Case report and literature review , 2020, The journal of obstetrics and gynaecology research.

[61]  E. Poluzzi,et al.  Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis , 2020, Drug Safety.

[62]  Manuel J. Rodriguez,et al.  Acute Liver Failure Associated With Ulipristal Acetate: A Case Report. , 2020, The American journal of gastroenterology.

[63]  A. Nader,et al.  Drug–Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy , 2020, Clinical Pharmacokinetics.

[64]  K. Barnhart,et al.  Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids , 2020, American journal of obstetrics and gynecology.

[65]  M. Avigan,et al.  An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids , 2020, Drug Safety.

[66]  M. Martinho,et al.  Management of symptomatic uterine fibroids with ulipristal acetate: a retrospective, multicentric and nationwide study. , 2020, Journal of gynecology obstetrics and human reproduction.

[67]  S. Khanduri,et al.  Evaluation of 25-hydroxy vitamin D3 levels in patients with a fibroid uterus , 2020, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[68]  J. Vandromme,et al.  Suspension of ulipristal acetate for uterine fibroids during ongoing EMA’s review of liver injury risk: Unfortunate timing during the Covid-19 pandemic! , 2020, European Journal of Obstetrics, Gynecology, and Reproductive Biology.

[69]  Qiwei Yang,et al.  Vitamin D3 Ameliorates DNA Damage Caused by Developmental Exposure to Endocrine Disruptors in the Uterine Myometrial Stem Cells of Eker Rats , 2020, Cells.

[70]  T. Faustmann,et al.  Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2. , 2020, European journal of obstetrics, gynecology, and reproductive biology.

[71]  G. Morgante,et al.  Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids , 2020, Reproductive Biology and Endocrinology.

[72]  J. Segars,et al.  Simvastatin ameliorates altered mechanotransduction in uterine leiomyoma cells. , 2020, American journal of obstetrics and gynecology.

[73]  Jin-Woo Lee,et al.  Fisetin induces apoptosis in uterine leiomyomas through multiple pathways , 2020, Scientific Reports.

[74]  K. Barnhart,et al.  Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas , 2020, Obstetrics and gynecology.

[75]  P. Salucci,et al.  Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience , 2020, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[76]  EMA suspends licence for ulipristal acetate for uterine fibroids , 2020, Drug and Therapeutics Bulletin.

[77]  K. S. Mohd,et al.  Anti-Uterine Fibroid Effect of Standardized Labisia Pumila Var. Alata Extracts In Vitro and in Human Uterine Fibroid Cancer Xenograft Model. , 2020, Asian Pacific journal of cancer prevention : APJCP.

[78]  E. Latta,et al.  Pathologic Changes in Uterine Leiomyomas After Extended Treatment With Ulipristal Acetate , 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[79]  C. Flannery,et al.  The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. , 2019, The Journal of clinical endocrinology and metabolism.

[80]  G. Patelli,et al.  Ulipristal Acetate Efficacy in a Patient with Symptomatic Fibroid and Concomitant Pulmonary Embolism , 2020, Case reports in medicine.

[81]  J. Huirne,et al.  Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study. , 2020, European journal of obstetrics, gynecology, and reproductive biology.

[82]  A. Di Spiezio Sardo,et al.  Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study , 2020, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[83]  K. Barnhart,et al.  Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. , 2020, The New England journal of medicine.

[84]  S. Vitale,et al.  Preoperative Treatment with Ulipristal Acetate before Outpatient Hysteroscopic Myomectomy , 2020, Gynecologic and Obstetric Investigation.

[85]  Richard A. Anderson,et al.  Systematic review of pregnancy outcomes after fertility-preserving treatment of uterine fibroids. , 2020, Reproductive biomedicine online.

[86]  S. Luisi,et al.  Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis , 2020, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[87]  W. Catherino,et al.  Steroid hormones and hormone antagonists regulate the neural marker neurotrimin in uterine leiomyoma. , 2020, Fertility and sterility.

[88]  P. Benedetti Panici,et al.  Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases , 2019, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[89]  Xin Yan,et al.  Anti-tumor activity and linear-diarylheptanoids of herbal couple Curcumae Rhizoma-Sparganii Rhizoma and the single herbs. , 2019, Journal of ethnopharmacology.

[90]  F. Petraglia,et al.  Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study. , 2019, Fertility and sterility.

[91]  M. Nisolle,et al.  Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[92]  Kam Y. J. Zhang,et al.  EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model , 2019, Scientific Reports.

[93]  Y. Osuga,et al.  Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. , 2019, Fertility and sterility.

[94]  C. Rubod,et al.  Disappearance of a myoma after pregnancy in a 38 years old patient, treated by ulipristal acetate without success before getting pregnant. , 2019, Journal of gynecology obstetrics and human reproduction.

[95]  E. Myers,et al.  A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids , 2019, Human reproduction open.

[96]  Y. Maejima,et al.  Ulipristal acetate for Japanese women with symptomatic uterine fibroids: A double‐blind, randomized, phase II dose‐finding study , 2019, Reproductive medicine and biology.

[97]  P. Dundr,et al.  Laparoscopic myomectomy after or without pre-treatment with ulipristal acetate , 2019, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

[98]  J. Huirne,et al.  Ulipristal acetate vs gonadotropin‐releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Short‐term results of a double‐blind randomized controlled trial , 2019, Acta obstetricia et gynecologica Scandinavica.

[99]  So-Jin Shin,et al.  Gyejibongnyeong-Hwan (Gui Zhi Fu Ling Wan) Ameliorates Human Uterine Myomas via Apoptosis , 2019, Front. Pharmacol..

[100]  Cheng Peng,et al.  Transcriptional profiling of uterine leiomyoma rats treated by a traditional herb pair, Curcumae rhizoma and Sparganii rhizoma , 2019, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[101]  J. Varinot,et al.  Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium. , 2019, Reproductive biomedicine online.

[102]  Betty S. Liu,et al.  Evidence of biomechanical and collagen heterogeneity in uterine fibroids , 2019, PloS one.

[103]  L. Shulman,et al.  Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas , 2019, Obstetrics and gynecology.

[104]  W. Catherino,et al.  Ulipristal acetate decreases active TGF-β3 and its canonical signaling in uterine leiomyoma via two novel mechanisms. , 2019, Fertility and sterility.

[105]  B. Jee,et al.  Adverse symptoms during short‐term use of ulipristal acetate in women with uterine myomas and/or adenomyosis , 2019, The journal of obstetrics and gynaecology research.

[106]  Lin,et al.  Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf.) Hull Extract and Active Compounds Inhibit Proliferation of Primary Human Leiomyoma Cells and Protect against Sexual Hormone-Induced Mice Smooth Muscle Hyperproliferation , 2019, Molecules.

[107]  E. Myers,et al.  Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials , 2019, Human reproduction.

[108]  Tzong-Ming Shieh,et al.  Natural Antioxidant Resveratrol Suppresses Uterine Fibroid Cell Growth and Extracellular Matrix Formation In Vitro and In Vivo , 2019, Antioxidants.

[109]  B. Eslami,et al.  The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D deficiency , 2019, Caspian journal of internal medicine.

[110]  Y. Osuga,et al.  Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial. , 2019, Obstetrics and gynecology.

[111]  A. Murji,et al.  Ulipristal Acetate for Disseminated Peritoneal Leiomyomatosis. , 2019, Obstetrics and gynecology.

[112]  J. Simon,et al.  Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. , 2019, Fertility and sterility.

[113]  U. Indraccolo,et al.  Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements , 2019, Recenti progressi in medicina.

[114]  W. Catherino,et al.  Ulipristal Acetate Mediates Decreased Proteoglycan Expression Through Regulation of Nuclear Factor of Activated T-Cells (NFAT5) , 2018, Reproductive Sciences.

[115]  G. Jakiel,et al.  Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy – 2 case studies , 2019, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[116]  J. Magnay.  Vilaprisan phase 2B trial: a timely efficacy and safety study of a novel selective progesterone receptor modulator for nonsurgical management of uterine fibroids. , 2019, Fertility and sterility.

[117]  Vinita Singh,et al.  Vitamin D3 Level in Women with Uterine Fibroid: An Observational Study in Eastern Indian Population , 2018, The Journal of Obstetrics and Gynecology of India.

[118]  Qiwei Yang,et al.  1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids , 2018, Reproductive Sciences.

[119]  J. Segars,et al.  Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production. , 2018, Fertility and sterility.

[120]  E. Zupi,et al.  Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[121]  C. Ros,et al.  Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. , 2018, Journal of minimally invasive gynecology.

[122]  A. Alcalde Dominguez,et al.  Therapy with Ulipristal Acetate in a Hypertensive Patient , 2018, Case reports in medicine.

[123]  L. Shulman,et al.  Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial. , 2018, Obstetrics and gynecology.

[124]  N. Watts,et al.  Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. , 2018, Obstetrics and gynecology.

[125]  K. S. Mohd,et al.  Orthosiphon stamineus Extracts Inhibits Proliferation and Induces Apoptosis in Uterine Fibroid Cells , 2018, Asian Pacific journal of cancer prevention : APJCP.

[126]  Qiwei Yang,et al.  Hypovitaminosis D exacerbates the DNA damage load in human uterine fibroids, which is ameliorated by vitamin D3 treatment , 2018, Acta Pharmacologica Sinica.

[127]  Ulipristal acetate (Esmya): restrictions on use , 2018, Drug and Therapeutics Bulletin.

[128]  Hsuan-Liang Liu,et al.  Resveratrol inhibits human leiomyoma cell proliferation via crosstalk between integrin αvβ3 and IGF-1R. , 2018, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[129]  P. Driggers,et al.  A-Kinase Anchoring Protein 13 (AKAP13) Augments Progesterone Signaling in Uterine Fibroid Cells , 2018, The Journal of clinical endocrinology and metabolism.

[130]  M. Sütterlin,et al.  Changes in sexuality during ulipristal acetate treatment in women with symptomatic uterine fibroids. , 2018, European journal of obstetrics, gynecology, and reproductive biology.

[131]  R. Raffaelli,et al.  Influence of Ulipristal Acetate Therapy on Uterine Fibroid‐Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound , 2018, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[132]  H. Abou-Taleb,et al.  Human uterine leiomyoma contains low levels of 1, 25 dihdroxyvitamin D3, and shows dysregulated expression of vitamin D metabolizing enzymes. , 2018, European journal of obstetrics, gynecology, and reproductive biology.

[133]  E. Marbaix,et al.  Gene expression changes in uterine myomas in response to ulipristal acetate treatment. , 2018, Reproductive biomedicine online.

[134]  A. Al-Hendy,et al.  Diet-induced vitamin D deficiency triggers inflammation and DNA damage profile in murine myometrium , 2018, International journal of women's health.

[135]  So-Jin Shin,et al.  Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix , 2018, International journal of molecular medicine.

[136]  Josep Estadella,et al.  Ulipristal acetate for the management of acute heavy menstrual bleeding without fibroids , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[137]  M. Hirsch,et al.  Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial. , 2018, Obstetrics and gynecology.

[138]  T. Simoncini,et al.  Ulipristal Acetate Interferes With Actin Remodeling Induced by 17β-Estradiol and Progesterone in Human Endometrial Stromal Cells , 2018, Front. Endocrinol..

[139]  P. Milart,et al.  Comparison of the influence of three fibroid treatment options: supracervical hysterectomy, ulipristal acetate and uterine artery embolization on ovarian reserve – an observational study , 2018, Journal of Ovarian Research.

[140]  M. K. Kim,et al.  Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate. , 2018, European journal of obstetrics, gynecology, and reproductive biology.

[141]  P. Henriet,et al.  Matrix Metalloproteinase Activity Correlates With Uterine Myoma Volume Reduction After Ulipristal Acetate Treatment , 2018, The Journal of clinical endocrinology and metabolism.

[142]  S. Irani,et al.  Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital , 2018, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[143]  G. Jakiel,et al.  Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids. , 2018, Fertility and sterility.

[144]  A. Messori,et al.  Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs. , 2018, European journal of obstetrics, gynecology, and reproductive biology.

[145]  J. Brun,et al.  Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy. , 2018, European journal of obstetrics, gynecology, and reproductive biology.

[146]  S. Erkaya,et al.  25-Hydroxy vitamin D levels in premenopausal Turkish women with uterine leiomyoma , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[147]  J. Segars,et al.  Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial. , 2018, Obstetrics and gynecology.

[148]  W. Catherino,et al.  Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial , 2018, Reproductive Sciences.

[149]  D. Habek,et al.  Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma , 2018, Journal of clinical pharmacy and therapeutics.

[150]  K. Kortekaas,et al.  Non-surgical intervention for retroperitoneal lymphogenic and pulmonary metastases of a benign leiomyoma: treatment with ulipristal acetate , 2018, BMJ Case Reports.

[151]  E. Marbaix,et al.  Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation , 2017, Gynecologic and Obstetric Investigation.

[152]  M. Henriksson,et al.  Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis , 2017, ClinicoEconomics and outcomes research : CEOR.

[153]  T. Ignatov,et al.  Endometrial cancer after ulipristal acetate for uterine fibroma. , 2017, European journal of obstetrics, gynecology, and reproductive biology.

[154]  M. Wais,et al.  A Multicenter Study Evaluating the Effect of Ulipristal Acetate during Myomectomy. , 2017, Journal of minimally invasive gynecology.

[155]  Henry W. Long,et al.  Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling , 2017, Oncotarget.

[156]  M. Schultze-Mosgau,et al.  Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women , 2017, Journal of clinical pharmacology.

[157]  C. Bergeron,et al.  Endometrial Changes in Surgical Specimens of Perimenopausal Patients Treated With Ulipristal Acetate for Uterine Leiomyomas , 2017, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[158]  P. Kadhel,et al.  Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma. , 2017, Journal of gynecology obstetrics and human reproduction.

[159]  E. Darai,et al.  Real-world data of 197 patients treated with ulipristal acetate for uterine fibroids: PREMYA study French population main outcomes. , 2017, Journal of gynecology obstetrics and human reproduction.

[160]  M. Dong,et al.  Protective effect of Rhus verniciflua Stokes extract in an experimental model of post-menopausal osteoporosis , 2017, Anatomy & cell biology.

[161]  H. Fernandez,et al.  Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France , 2017, BMJ Open.

[162]  A. Messori,et al.  Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women , 2017, ClinicoEconomics and outcomes research : CEOR.

[163]  Zhengyu Jin,et al.  Impact of germination on nutritional and physicochemical properties of adlay seed (Coixlachryma-jobi L.). , 2017, Food chemistry.

[164]  A. Soliman,et al.  Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. , 2017, Fertility and sterility.

[165]  S. Kives,et al.  Does Ulipristal Acetate Affect Surgical Experience at Laparoscopic Myomectomy? , 2017, Journal of minimally invasive gynecology.

[166]  M. Powell,et al.  An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome , 2017, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[167]  D. Barlow,et al.  Safety after extended repeated use of ulipristal acetate for uterine fibroids , 2017, PloS one.

[168]  M. Postma,et al.  Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis , 2017, Journal of medical economics.

[169]  P. Saunders,et al.  Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium , 2017, Human reproduction.

[170]  M. K. Kim,et al.  Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist , 2017, Obstetrics & gynecology science.

[171]  Zhaoxia Ding,et al.  Mechanistic Study of the Inhibitory Effect of Kaempferol on Uterine Fibroids In Vitro , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[172]  O. Istre.  Unexpected Uterine Leiomyosarcoma During Laparoscopic Hysterectomy Treated 6 Months With Ulipristal Acetate and Contained Power Morcellation. , 2016, Journal of minimally invasive gynecology.

[173]  F. Guilak,et al.  Loss of stiffness in collagen-rich uterine fibroids after digestion with purified collagenase Clostridium histolyticum. , 2016, American journal of obstetrics and gynecology.

[174]  Q. Dou,et al.  Biological and Mechanistic Characterization of Novel Prodrugs of Green Tea Polyphenol Epigallocatechin Gallate Analogs in Human Leiomyoma Cell Lines , 2016, Journal of cellular biochemistry.

[175]  S. Ferrero,et al.  Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. , 2016, European journal of obstetrics, gynecology, and reproductive biology.

[176]  K. Yu,et al.  Rhus verniciflua Stokes attenuates cholestatic liver cirrhosis-induced interstitial fibrosis via Smad3 down-regulation and Smad7 up-regulation , 2016, Anatomy & cell biology.

[177]  J. Donnez,et al.  Uterine fibroid management: from the present to the future , 2016, Human reproduction update.

[178]  O. Ceci,et al.  Hysteroscopic Patterns in Women on Treatment With Ulipristal Acetate 5 mg/day: A Preliminary Study. , 2016, Journal of minimally invasive gynecology.

[179]  X. Ye,et al.  Role of ethnicity in treating uterine fibroids with ulipristal acetate. , 2016, Fertility and sterility.

[180]  M. Mhallem,et al.  Long-term nonsurgical control with ulipristal acetate of multiple uterine fibroids, enabling pregnancy. , 2016, American journal of obstetrics and gynecology.

[181]  J. Dubuisson,et al.  Myoma migration: an unexpected "effect" with Ulipristal acetate treatment. , 2016, European review for medical and pharmacological sciences.

[182]  L. Nieman,et al.  Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report. , 2016, The Journal of reproductive medicine.

[183]  S. Ferrero,et al.  Ulipristal Acetate Before High Complexity Hysteroscopic Myomectomy: A Retrospective Comparative Study. , 2016, Journal of minimally invasive gynecology.

[184]  D. Maratea.  Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation. , 2016, Minerva ginecologica.

[185]  T. Boyer,et al.  Vitamin D3 Inhibits Wnt/β-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. , 2016, The Journal of clinical endocrinology and metabolism.

[186]  S. Ferrero,et al.  Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. , 2015, European journal of obstetrics, gynecology, and reproductive biology.

[187]  Cheng Yan,et al.  Chemical Composition, Antioxidative and Anticancer Activities of the Essential Oil: Curcumae Rhizoma–Sparganii Rhizoma, a Traditional Herb Pair , 2015, Molecules.

[188]  Tung-Ti Chang,et al.  Prescription patterns of Chinese herbal products for patients with uterine fibroid in Taiwan: A nationwide population-based study. , 2015, Journal of ethnopharmacology.

[189]  J. Y. Kim,et al.  Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. , 2015, European journal of obstetrics, gynecology, and reproductive biology.

[190]  M. Motamedi,et al.  Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study. , 2015, American journal of obstetrics and gynecology.

[191]  E. Marbaix,et al.  In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. , 2015, Fertility and sterility.

[192]  P. Milart,et al.  Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three‐dimensional ultrasound: prospective observational study , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[193]  L. Matytsina-Quinlan,et al.  Abnormal excessive per vagina (PV) bleeding on Esmya–selective progesterone receptor modulator (SPRM) in a symptomatic patient with uterine fibroid , 2015, BMJ Case Reports.

[194]  R. Goeree,et al.  Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management , 2015, ClinicoEconomics and outcomes research : CEOR.

[195]  I. Osterloh,et al.  Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. , 2015, Fertility and sterility.

[196]  A. El-Sohemy,et al.  1,25-dihydroxyvitamin D3 regulates expression of sex steroid receptors in human uterine fibroid cells. , 2015, The Journal of clinical endocrinology and metabolism.

[197]  Sukhbir S. Singh,et al.  Contemporary management of uterine fibroids: focus on emerging medical treatments , 2015, Current medical research and opinion.

[198]  Z. Kaló,et al.  Economic Evaluation of Ulipristal Acetate for the Treatment of Patients With Moderate and Severe Symptoms of Uterine Fibroids in Romania. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[199]  J. Donnez,et al.  First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. , 2014, Fertility and sterility.

[200]  C. Yallampalli,et al.  Simvastatin Potently Induces Calcium-dependent Apoptosis of Human Leiomyoma Cells* , 2014, The Journal of Biological Chemistry.

[201]  J. Fagart,et al.  Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[202]  A. Pellicer,et al.  Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids , 2014, Case reports in obstetrics and gynecology.

[203]  F. Petraglia,et al.  Ulipristal Acetate Modulates the Expression and Functions of Activin A in Leiomyoma Cells , 2014, Reproductive Sciences.

[204]  A. Al-Hendy,et al.  Green Tea Extract Inhibition of Human Leiomyoma Cell Proliferation Is Mediated via Catechol-O-Methyltransferase , 2014, Gynecologic and Obstetric Investigation.

[205]  A. Al-Hendy,et al.  Paricalcitol, a Vitamin D Receptor Activator, Inhibits Tumor Formation in a Murine Model of Uterine Fibroids , 2014, Reproductive Sciences.

[206]  I. Osterloh,et al.  Long-term treatment of uterine fibroids with ulipristal acetate ☆. , 2014, Fertility and sterility.

[207]  Z. Kaló,et al.  The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. , 2014, European journal of obstetrics, gynecology, and reproductive biology.

[208]  D. Barlow,et al.  Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. , 2014, Human reproduction.

[209]  P. Milart,et al.  The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up , 2014, Przeglad menopauzalny = Menopause review.

[210]  Aamir T Khan,et al.  Uterine fibroids: current perspectives , 2014, International journal of women's health.

[211]  Jian-ping Liu,et al.  Chinese herbal medicine Guizhi Fuling Formula for treatment of uterine fibroids: a systematic review of randomised clinical trials , 2014, BMC Complementary and Alternative Medicine.

[212]  K. Osteen,et al.  1,25-Dihydroxyvitamin D3 Reduces Extracellular Matrix-Associated Protein Expression in Human Uterine Fibroid Cells1 , 2013, Biology of reproduction.

[213]  K. Osteen,et al.  Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. , 2013, Human reproduction.

[214]  A. Al-Hendy,et al.  Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study , 2013, International journal of women's health.

[215]  A. Al-Hendy,et al.  Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study , 2013, International journal of women's health.

[216]  Wei Liu,et al.  A polysaccharide fraction of adlay seed (Coixlachryma-jobi L.) induces apoptosis in human non-small cell lung cancer A549 cells. , 2013, Biochemical and biophysical research communications.

[217]  D. Barlow,et al.  Endometrial Morphology After Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator, Ulipristal Acetate , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[218]  C. Kuo,et al.  Adlay (薏苡 yì yĭ; “soft-shelled job's tears”; the seeds of Coix lachryma-jobi L. var. ma-yuen Stapf) is a Potential Cancer Chemopreventive Agent toward Multistage Carcinogenesis Processes , 2012, Journal of traditional and complementary medicine.

[219]  P. Forgez,et al.  Ulipristal acetate does not impact human normal breast tissue. , 2012, Human reproduction.

[220]  O. Ameer,et al.  Orthosiphon stamineus: traditional uses, phytochemistry, pharmacology, and toxicology. , 2012, Journal of medicinal food.

[221]  J. Yager.  Catechol-O-methyltransferase: characteristics, polymorphisms and role in breast cancer. , 2012, Drug discovery today. Disease mechanisms.

[222]  A. Al-Hendy,et al.  1,25-Dihydroxyvitamin D3 Treatment Shrinks Uterine Leiomyoma Tumors in the Eker Rat Model1 , 2012, Biology of reproduction.

[223]  I. Osterloh,et al.  Ulipristal acetate versus leuprolide acetate for uterine fibroids. , 2012, The New England journal of medicine.

[224]  I. Osterloh,et al.  Ulipristal acetate versus placebo for fibroid treatment before surgery. , 2012, The New England journal of medicine.

[225]  A. Al-Hendy,et al.  Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model. , 2011, Human reproduction.

[226]  Yong Zeng,et al.  Effects of adlay seed oil on blood lipids and antioxidant capacity in hyperlipidemic rats. , 2011, Journal of the science of food and agriculture.

[227]  P. Nallari,et al.  The Genetic Bases of Uterine Fibroids; A Review , 2011, Journal of reproduction & infertility.

[228]  Md Soriful Islam,et al.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. , 2011, Human reproduction update.

[229]  T. Hitaka,et al.  Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. , 2011, Journal of medicinal chemistry.

[230]  M. B. Bridgeman,et al.  Ulipristal Acetate (ella): A Selective Progesterone Receptor Modulator For Emergency Contraception. , 2011, P & T : a peer-reviewed journal for formulary management.

[231]  M. Broder,et al.  FIGO classification system (PALM‐COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age , 2011, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[232]  M. López-Lázaro,et al.  A review on the dietary flavonoid kaempferol. , 2011, Mini reviews in medicinal chemistry.

[233]  A. Al-Hendy,et al.  1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. , 2011, The Journal of clinical endocrinology and metabolism.

[234]  A. Malik,et al.  Medicinal Potentials Of Orthosiphon Stamineus Benth. , 2010 .

[235]  A. Al-Hendy,et al.  Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. , 2010, Fertility and sterility.

[236]  C. Tekcan,et al.  Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. , 2010, Fertility and sterility.

[237]  A. Al-Hendy,et al.  Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. , 2010, American journal of obstetrics and gynecology.

[238]  P. Heinonen,et al.  Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. , 2009, Fertility and sterility.

[239]  I. Cameron,et al.  Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. , 2008, The Journal of clinical endocrinology and metabolism.

[240]  R. Andrews,et al.  Uterine Artery Embolization: A Safe and Effective, Minimally Invasive, Uterine-Sparing Treatment Option for Symptomatic Fibroids , 2008, Seminars in interventional radiology.

[241]  T. Maruo,et al.  Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. , 2008, Human reproduction.

[242]  T. Maruo,et al.  Comparative Effects of SPRM Asoprisnil (J867) on Proliferation, Apoptosis, and the Expression of Growth Factors in Cultured Uterine Leiomyoma Cells and Normal Myometrial Cells , 2007, Reproductive Sciences.

[243]  T. Maruo,et al.  Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells. , 2007, American journal of physiology. Endocrinology and metabolism.

[244]  I. Cameron,et al.  The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. , 2007, Human reproduction.

[245]  K. Chwalisz,et al.  A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. , 2007, Fertility and sterility.

[246]  T. Maruo,et al.  A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. , 2007, The Journal of clinical endocrinology and metabolism.

[247]  M. De Falco,et al.  [GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: literature review]. , 2006, Minerva ginecologica.

[248]  M. Munro,et al.  Myolysis of Uterine Fibroids: Is There a Role? , 2006, Clinical obstetrics and gynecology.

[249]  A. Al-Hendy,et al.  Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas. , 2006, Fertility and sterility.

[250]  T. Maruo,et al.  A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. , 2006, Human reproduction.

[251]  T. Maruo,et al.  A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. , 2006, The Journal of clinical endocrinology and metabolism.

[252]  K. Chwalisz,et al.  Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy , 2003, Steroids.

[253]  B. Xiao,et al.  Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. , 2003, Fertility and sterility.

[254]  K. Chwalisz,et al.  Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity , 2000, Steroids.

[255]  A. Schally,et al.  Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. , 1997, Human reproduction.

[256]  E. Wallach,et al.  Uterine leiomyomata: etiology, symptomatology, and management. , 1981, Fertility and sterility.

[257]  C. Ros,et al.  Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: Exploratory findings at a tertiary referral center. , 2019, European journal of obstetrics, gynecology, and reproductive biology.

[258]  C. Ionescu,et al.  UPA effects on endometrium - what is the significance? , 2018, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[259]  S. Islam,et al.  Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report. , 2017, Pathology, research and practice.

[260]  J. Vandromme,et al.  Medical or surgical management of fibroids? An internet survey of gynecologists' views. , 2017, Maturitas.

[261]  D. Barlow,et al.  Long-term medical management of uterine fibroids with ulipristal acetate. , 2016, Fertility and sterility.

[262]  K. Murad.  Spontaneous Pregnancy Following Ulipristal Acetate Treatment in a Woman with a Symptomatic Uterine Fibroid. , 2016, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[263]  G. Lo Monte,et al.  Ulipristal acetate prior to in vitro fertilization in a female patient affected by uterine fibroids: a case report. , 2016, European review for medical and pharmacological sciences.

[264]  M. Wielgoś,et al.  Application of ulipristal acetate in female patients with uterine fibroids. , 2014, Neuro endocrinology letters.

[265]  A. Al-Hendy,et al.  Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. , 2011, Fertility and sterility.

[266]  H. Yoshino,et al.  Pharmacotherapeutic effects of kuei-chih-fu-ling-wan (keishi-bukuryo-gan) on human uterine myomas. , 1992, The American journal of Chinese medicine.